Bolt Biotherapeutics, Inc. (BOLT)

Compare

0.3600

-0.0354

(-8.95%)

At close: April 4 at 4:00:00 PM EDT

0.3888

+0.03

+(8.00%)

After hours: April 4 at 7:03:09 PM EDT

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. BDC-3042 is a proprietary agonist antibody th

GlobeNewswire 10 days ago

BOLT
-8.95%
Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot

The Redwood City, California-based company said it had a loss of 42 cents per share. Losses, adjusted for asset impairment costs, came to 38 cents per share. The results met Wall Street expectations.

Associated Press Finance 11 days ago

BOLT
-8.95%
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported in second quarter 2025Cash balance of $70.2 million as of December 31, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing nov

GlobeNewswire 11 days ago

BOLT
-8.95%
Bolt Biotherapeutics to Participate in Upcoming March Conferences

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 45th Annual Health Care ConferenceCompany presentation on Tuesday, March 4, 2025 at 3:10 p.m. EST (1:10 p.m. PST) Leerink Partners Global Healthcare ConferenceParticipating in 1x1 meetings on Monday, March

GlobeNewswire last month

BOLT
-8.95%
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The collaborators are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing Joint Development a

GlobeNewswire last month

BOLT
-8.95%
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations

Bolt Biotherapeutics ( NASDAQ:BOLT ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.14m (down 55% from...

Simply Wall St. 4 months ago

BOLT
-8.95%
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -11.11% and 12.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

BOLT
-8.95%
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot

BOLT) on Tuesday reported a loss of $15.2 million in its third quarter. The Redwood City, California-based company said it had a loss of 40 cents per share. The results did not meet Wall Street expectations.

Associated Press Finance 4 months ago

BOLT
-8.95%
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose-escalation trial of BDC-1001 at the SITC 39th Annual MeetingBDC-4182 on track to start clinical trial in second quarter 2025Cash balance of $84.4 million as of September 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) --

GlobeNewswire 4 months ago

BOLT
-8.95%
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 4 months ago

BOLT
-8.95%
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the tre

GlobeNewswire 4 months ago

BOLT
-8.95%
Bolt Biotherapeutics Announces Changes to its Board of Directors

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sof

GlobeNewswire 6 months ago

BOLT
-8.95%
Bolt Biotherapeutics to Participate in Upcoming September Conferences

REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside chat on Friday, Sept. 6, at 7:00 a.m. EDT (4:00 a.m. PDT)H.C. Wainwright 26th Annual Global Investment ConferenceCompany presentation available on

GlobeNewswire 7 months ago

BOLT
-8.95%
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingCash balance of $97.5 million as of June 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developi

GlobeNewswire 7 months ago

BOLT
-8.95%
The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows

Global stocks are surging. The MSCI ACWI Index, which encompasses both developed and emerging markets, reached another all-time high, continuing its record-breaking streak. This milestone is part of a broader trend in global equity markets, with 14 out of the world’s 20 largest stock exchanges recently setting new records. In contrast to this general market uplift, stocks with analyst uncertainty remain a notable exception, where divergent views among experts signal potential volatility and risk

InvestorPlace 10 months ago

BIDU

UAA

BOLT
-8.95%
Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...

Key updates include leadership changes, significant workforce reduction, and promising developments in cancer treatment trials.

GuruFocus.com 10 months ago

BOLT
-8.95%
Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

The company will cut its workforce by half and shuffle leadership as it discontinues testing of the drug trastuzumab imbotolimod.

BioPharma Dive 10 months ago

BOLT
-8.95%
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Dev

GlobeNewswire 10 months ago

BOLT
-8.95%
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 10 months ago

BOLT
-8.95%

Performance Overview

Return	BOLT	S&P 500 (^GSPC)
YTD	-32.71%	-13.73%
1-Year	-72.93%	-1.42%
3-Year	-87.50%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates

Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics Announces Changes to its Board of Directors

Bolt Biotherapeutics to Participate in Upcoming September Conferences

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows

Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...

Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Performance Overview